ATE218063T1 - Viral verursachte zerstörung von neoplastzellen - Google Patents

Viral verursachte zerstörung von neoplastzellen

Info

Publication number
ATE218063T1
ATE218063T1 AT91308439T AT91308439T ATE218063T1 AT E218063 T1 ATE218063 T1 AT E218063T1 AT 91308439 T AT91308439 T AT 91308439T AT 91308439 T AT91308439 T AT 91308439T AT E218063 T1 ATE218063 T1 AT E218063T1
Authority
AT
Austria
Prior art keywords
neoplastic cells
caused destruction
viral caused
viral
destruction
Prior art date
Application number
AT91308439T
Other languages
English (en)
Inventor
Robert L Martuza
Donald M Coen
Original Assignee
Gen Hospital Corp
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Harvard College filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE218063T1 publication Critical patent/ATE218063T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT91308439T 1990-09-14 1991-09-16 Viral verursachte zerstörung von neoplastzellen ATE218063T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58205790A 1990-09-14 1990-09-14

Publications (1)

Publication Number Publication Date
ATE218063T1 true ATE218063T1 (de) 2002-06-15

Family

ID=24327661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91308439T ATE218063T1 (de) 1990-09-14 1991-09-16 Viral verursachte zerstörung von neoplastzellen

Country Status (5)

Country Link
EP (1) EP0514603B1 (de)
JP (1) JP3386479B2 (de)
AT (1) ATE218063T1 (de)
CA (1) CA2051289C (de)
DE (1) DE69133022T2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
CA2152941C (en) * 1993-02-16 2003-04-22 Francis Mccormick Cytopathic viruses for therapy and prophylaxis of neoplasia
EP0759695B1 (de) * 1994-05-13 2006-11-08 Thomas Jefferson University Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
AU7258996A (en) * 1995-10-06 1997-04-28 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
NZ518945A (en) * 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
CA2327506A1 (en) 1998-04-30 1999-11-04 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
ZA200203041B (en) 1999-11-12 2003-12-09 Oncolytics Biotech Inc Viruses for the treatment of cellular proliferative disorders.
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883662A (en) * 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
GB8712528D0 (en) * 1987-05-28 1987-07-01 Clayton Found Res Gene transfer
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells

Also Published As

Publication number Publication date
CA2051289A1 (en) 1992-03-15
DE69133022D1 (de) 2002-07-04
CA2051289C (en) 2002-11-26
JP3386479B2 (ja) 2003-03-17
EP0514603A1 (de) 1992-11-25
JPH06100458A (ja) 1994-04-12
DE69133022T2 (de) 2003-01-02
EP0514603B1 (de) 2002-05-29

Similar Documents

Publication Publication Date Title
ATE218063T1 (de) Viral verursachte zerstörung von neoplastzellen
DK1201639T3 (da) Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser
ES2157109T3 (es) Virus citopaticos para el tratamiento y la profilasis de la neoplasia.
DK0858330T3 (da) Præparater indeholdende derivater af hydroperoxyeicosatetraensyre og fremgangsmåder til anvendelse ved behandling af sygdom
NO922275L (no) Aryletere, deres fremstilling og fremgangsmaate for behandling
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
DK0652957T3 (da) Samlede viruspartikler og deres anvendelse i en vaccine imod rotaviral sygdom
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
NO953329L (no) Rekombinante viruser og deres anvendelse i genterapien for behandling av öyesykdommer
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
ES2036526T3 (es) Composiciones de interferon.
PT888114E (pt) Utilizacao de (+)-alfa-(2,3-dimetoxifenil)-1-¬2-(4-fluorofenil)etil|-4-piperidinometanol no tratamento de doencas depressivas e doencas bipolares
DE69524388D1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
ES2149791T3 (es) Procedimiento para la inactivacion de virus en preparaciones de proteinas.
ATE70181T1 (de) Verwendung von oxochinazolinderivaten bei der behandlung von hyperurikaemie.
ES507444A0 (es) Procedimiento para inactivar virus de la fiebre aftosa.
ATE91419T1 (de) Synergistische kombination zur ophthalmischen verwendung.
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
DK0661058T3 (da) Anvendelse af bradykininantagonister til behandling af virussygdomme
NO895089D0 (no) Polymerblandinger og fremgangsmaate for deres fremstilling.
DE3668778D1 (de) Vorrichtung zur laserchirurgie und insbesondere zur keratotomie der cornea (iii).
DK0891778T3 (da) TCF-II til forebyggelse og/eller behandling af stråleinducerede lidelser
DE59407576D1 (de) Verwendung von Etofibrat und pharmazeutische Zusammensetzungen, enthaltend Etofibrat, zur Behandlung der diabetischen Angio- und Retinopathie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties